Ajanta Pharma · NSE: AJANTPHARM · BSE: 532331
Q1 FY21 results · Apr–Jun 2020
Ajanta Pharma reported revenue from operations of ₹668.20 crore (up 9.2% from Q1 FY20) and net profit of ₹147.76 crore (up 28.9% from Q1 FY20) for Q1 FY21 (Apr–Jun 2020), on a consolidated basis.
| Item | Q1 FY21 | Q1 FY20 | YoY | Q4 FY20 | QoQ |
|---|---|---|---|---|---|
| Revenue from operations | 668.20 | 611.94 | +9.2% | 681.96 | −2.0% |
| Other income | 13.12 | 7.64 | +71.7% | 56.69 | −76.9% |
| Total income | 681.32 | 619.58 | +10.0% | 738.65 | −7.8% |
| Profit before tax | 206.69 | 151.45 | +36.5% | 175.86 | +17.5% |
| Net profit for the period | 147.76 | 114.63 | +28.9% | 129.16 | +14.4% |
| EPS, basic (₹) | 16.93 | 13.14 | +28.8% | 14.80 | +14.4% |
| Net margin (%) | 22.1 | 18.7 | 18.9 |
| Item | Q1 FY21 | Q1 FY20 | YoY | Q4 FY20 | QoQ |
|---|---|---|---|---|---|
| Revenue from operations | 560.85 | 545.74 | +2.8% | 560.68 | +0.0% |
| Other income | 13.10 | 39.62 | −66.9% | 54.10 | −75.8% |
| Total income | 573.95 | 585.36 | −1.9% | 614.78 | −6.6% |
| Profit before tax | 158.47 | 156.45 | +1.3% | 129.62 | +22.3% |
| Net profit for the period | 115.69 | 123.60 | −6.4% | 88.51 | +30.7% |
| EPS, basic (₹) | 13.26 | 14.17 | −6.4% | 10.14 | +30.8% |
| Net margin (%) | 20.6 | 22.6 | 15.8 |
Consolidated
- Filed with BSE
- 31 Jul 2020, 12:14 IST
- Board meeting
- 30 Jul 2020
- Period
- 01 Apr 2020 to 30 Jun 2020
- Review status
- Unaudited
- Source
- XBRL filing on BSE
Standalone
- Filed with BSE
- 31 Jul 2020, 12:14 IST
- Board meeting
- 30 Jul 2020
- Period
- 01 Apr 2020 to 30 Jun 2020
- Review status
- Unaudited
- Source
- XBRL filing on BSE